Linked Life Data

17145574

Source:http://linkedlifedata.com/resource/pubmed/id/17145574

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2006-12-5
pubmed:abstractText
A phase II trial evaluating 6% topical miltefosine solution was performed in 12 pretreated patients with cutaneous T-cell lymphoma. Miltefosine (Miltex) was administered for 8 weeks, once per day during the first week then twice every day for seven weeks. Main side effects consisted in moderate to mild pruritus or desquamation in 57 % and 50 % of patients, respectively. No systemic nor biological toxicity was observed. This treatment was administered on an outpatient basis exclusively. The overall response rate was 58 % with a median duration of response of 12 months. Miltefosine is a safe, simple and effective treatment in certain patients with cutaneous T-cell lymphoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1769-6917
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
93
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
E115-8
pubmed:dateRevised
2011-4-5
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
pubmed:affiliation
Service d'Hématologie, CH Lyon-Sud, Pierre-Bénite, Laboratoire d'Hématologie, Pavillon E, Hôpital Edouard-Herriot, 5 place d'Arsonval, 69003 Lyon Cedex 03, France. charles.dumontet@chu-lyon.fr
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II